Japan's Takeda, Dainippon get EU nod for schizophrenia drug

TOKYO, March 31 Sun Mar 30, 2014 7:29pm EDT

Related Topics

TOKYO, March 31 (Reuters) - Takeda Pharmaceutical Co Ltd and Dainippon Sumitomo Pharma Co Ltd said on Monday the European Commission had given them marketing authorisation for Latuda, a once-a-day oral treatment for schizophrenia in adults.

Sunovion Pharmaceuticals Europe Ltd, a subsidiary of Dainippon Sumitomo Pharma, will market Latuda in the UK, and Takeda subsidiaries will market the drug across Europe, they said in a joint statement. (Reporting by Dominic Lau; Editing by John Mair)

FILED UNDER:
A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article